These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1161 related items for PubMed ID: 31675993

  • 1. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
    Snider H, Villavarajan B, Peng Y, Shepherd LE, Robinson AC, Mueller CR.
    Clin Epigenetics; 2019 Nov 01; 11(1):155. PubMed ID: 31675993
    [Abstract] [Full Text] [Related]

  • 2. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
    West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, Sinnwell JP, Thompson KJ, Bowie KR, Harkless RV, Skor MN, Pierce CF, Styke SC, Kim CR, de Wet L, Greene GL, Boughey JC, Goetz MP, Kalari KR, Wang L, Fleming GF, Györffy B, Conzen SD.
    Clin Cancer Res; 2018 Jul 15; 24(14):3433-3446. PubMed ID: 29636357
    [Abstract] [Full Text] [Related]

  • 3. Large-scale analysis of DFNA5 methylation reveals its potential as biomarker for breast cancer.
    Croes L, Beyens M, Fransen E, Ibrahim J, Vanden Berghe W, Suls A, Peeters M, Pauwels P, Van Camp G, Op de Beeck K.
    Clin Epigenetics; 2018 Jul 15; 10():51. PubMed ID: 29682089
    [Abstract] [Full Text] [Related]

  • 4. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
    Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, Hoon DS.
    Breast Cancer Res; 2008 Jul 15; 10(3):R46. PubMed ID: 18485221
    [Abstract] [Full Text] [Related]

  • 5. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
    Ramezani F, Salami S, Omrani MD, Maleki D.
    Asian Pac J Cancer Prev; 2012 Jul 15; 13(2):451-7. PubMed ID: 22524805
    [Abstract] [Full Text] [Related]

  • 6. Frequent promoter hypermethylation and expression reduction of the glucocorticoid receptor gene in breast tumors.
    Nesset KA, Perri AM, Mueller CR.
    Epigenetics; 2014 Jun 15; 9(6):851-9. PubMed ID: 24622770
    [Abstract] [Full Text] [Related]

  • 7. Epigenetic regulation of ID4 in breast cancer: tumor suppressor or oncogene?
    Nasif D, Campoy E, Laurito S, Branham R, Urrutia G, Roqué M, Branham MT.
    Clin Epigenetics; 2018 Aug 23; 10(1):111. PubMed ID: 30139383
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.
    Wang HY, Park S, Kim S, Ahn S, Lee D, Kim S, Jung D, Park KH, Lee H.
    Int J Clin Exp Pathol; 2014 Aug 23; 7(9):5792-800. PubMed ID: 25337220
    [Abstract] [Full Text] [Related]

  • 9. DNA methylation of the glucocorticoid receptor gene promoter in the placenta is associated with blood pressure regulation in human pregnancy.
    Dwi Putra SE, Reichetzeder C, Meixner M, Liere K, Slowinski T, Hocher B.
    J Hypertens; 2017 Nov 23; 35(11):2276-2286. PubMed ID: 28817493
    [Abstract] [Full Text] [Related]

  • 10. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients.
    Martínez-Galán J, Torres-Torres B, Núñez MI, López-Peñalver J, Del Moral R, Ruiz De Almodóvar JM, Menjón S, Concha A, Chamorro C, Ríos S, Delgado JR.
    BMC Cancer; 2014 Feb 04; 14():59. PubMed ID: 24495356
    [Abstract] [Full Text] [Related]

  • 11. PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
    Venkatesh T, Shetty A, Chakraborti S, Suresh PS.
    J Cell Physiol; 2019 Feb 04; 234(2):1071-1079. PubMed ID: 30189107
    [Abstract] [Full Text] [Related]

  • 12. DNA methylation and hormone receptor status in breast cancer.
    Benevolenskaya EV, Islam AB, Ahsan H, Kibriya MG, Jasmine F, Wolff B, Al-Alem U, Wiley E, Kajdacsy-Balla A, Macias V, Rauscher GH.
    Clin Epigenetics; 2016 Feb 04; 8():17. PubMed ID: 26884818
    [Abstract] [Full Text] [Related]

  • 13. C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis.
    Pinto AE, André S, Pereira T, Nóbrega S, Soares J.
    Ann Oncol; 2001 Apr 04; 12(4):525-33. PubMed ID: 11398888
    [Abstract] [Full Text] [Related]

  • 14. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, Kim SW, Lee JE, Nam SJ.
    BMC Cancer; 2015 Mar 18; 15():138. PubMed ID: 25880075
    [Abstract] [Full Text] [Related]

  • 15. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2007 Sep 01; 25(25):3846-52. PubMed ID: 17679725
    [Abstract] [Full Text] [Related]

  • 16. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Lukas A, Müller V, Milde-Langosch K, Nährig J, Foekens J, Maier S, Schmitt M, Lesche R.
    J Clin Oncol; 2008 Nov 01; 26(31):5036-42. PubMed ID: 18711169
    [Abstract] [Full Text] [Related]

  • 17. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
    Wang Y, Gong X, Zhang Y.
    Biosci Rep; 2021 Sep 30; 41(9):. PubMed ID: 34406386
    [Abstract] [Full Text] [Related]

  • 18. Hyper-methylation of the upstream CpG island shore is a likely mechanism of GPER1 silencing in breast cancer cells.
    Manjegowda MC, Gupta PS, Limaye AM.
    Gene; 2017 May 30; 614():65-73. PubMed ID: 28286086
    [Abstract] [Full Text] [Related]

  • 19. Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer.
    van Hoesel AQ, van de Velde CJ, Kuppen PJ, Putter H, de Kruijf EM, van Nes JG, Giuliano AE, Hoon DS.
    Breast Cancer Res Treat; 2012 Feb 30; 131(3):859-69. PubMed ID: 21479925
    [Abstract] [Full Text] [Related]

  • 20. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
    Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Spyratos F, Foekens JA, Lesche R, Martens JW.
    BMC Cancer; 2010 Jun 01; 10():247. PubMed ID: 20515469
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.